Overview
- The agreement was signed through Lupin's wholly owned subsidiary, Lupin Atlantis Holdings SA (LAHSA).
- Galenicum will develop, manufacture and supply finished formulations of injectable Semaglutide.
- Lupin will manage regulatory submissions, approvals, commercialization and distribution across 23 markets spanning Canada, Europe, Southeast Asia and Latin America.
- Company leaders described the tie-up as a strategic step to expand access and scale supply in the GLP-1 category.
- Lupin shares eased following the announcement, closing 0.81% lower at Rs 2,160.60 on Tuesday.